Use of psychostimulants in patients with dementia

Annals of Pharmacotherapy

Volumn 44, Issue 10, 2010, Pages 1624-1632

  Dolder, Christian R ^a,b   Davis, Lauren Nicole ^a   McKinsey, Jonathan ^b  

^a WINGATE UNIVERSITY   (United States)

^b Carolinas Medical Center NorthEast   (United States)

Author keywords

Alzheimer's disease; Dementia; Methylphenidate; Psychostimulant

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; MEGLITINIDE; MITIGLINIDE; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MEDICAL SOCIETY; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PERIPHERAL EDEMA; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

AGED; APATHY; BEHAVIORAL SYMPTOMS; CENTRAL NERVOUS SYSTEM STIMULANTS; DEMENTIA; DISORDERS OF EXCESSIVE SOMNOLENCE; HUMANS; PSYCHOMOTOR AGITATION;

EID: 77957660750     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P341     Document Type: Review

References (84)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with Alzheimer's disease and other dementias, 2nd ed. www.psychiatryonline.com/pracGuide/PracticePDFs/AlzPG1010007.pdf (accessed 2010 Apr 5).
2. American Association for Geriatric Psychiatry. Principles of care for patients with dementia resulting from Alzheimer disease. www.aagpgpa.org/prof/ position-caredmnalz.asp (accessed 2010 Apr 5).
3. Hansen RA, Gartlehner G, Lohr KN, Kaufer DI. Functional outcomes of drug treatment in Alzheimer's disease: a systematic review and meta-analysis. Drugs Aging 2007;24:155-67.
4. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293:596-608. (Pubitemid 40171242)
5. Lanctot KL, Herrmann N, Black SE, et al. Apathy associated with Alzheimer disease: use of dextroamphetamine challenge. Am J Geriatr Psychiatry 2008;16:551-7.
6. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999;56:1388-93.
7. Herrmann N, Lanctot KL, Rothenburg LS, Eryavec G. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;23:116-9.
8. Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001;9:58-66.
9. Porsteinsson AP, Tariot PN, Jakimovich LJ, et al. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am J Geriatr Psychiatry 2003;11:434-40.
10. Sival RC, Duivenvoorden HJ, Jansen PA, Haffmans PM, Duursma SA, Eikelenboom P. Sodium valproate in aggressive behaviour in dementia: a twelve-week open label follow-up study. Int J Geriatr Psychiatry 2004;19:305-12.
11. Sival RC, Haffmans PM, Jansen PA, Duursma SA, Eikelenboom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia-a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002;17:579-85.
12. Tariot PN, Raman R, Jakimovich L, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry 2005;13:942-9.
13. Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007;15:942-52.
14. Siddique H, Hynan LS, Weiner MF. Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. J Clin Psychiatry 2009;70:915-8.
15. Reichman WE, Negron A. Negative symptoms in the elderly patient with dementia. Int J Geriatr Psychiatry 2001;16(suppl 1):S7-11.
16. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003;60:737-46.
17. Landes AM, Sperry SD, Strauss ME, Geldmacher DS. Apathy in Alzheimer's disease. J Am Geriatr Soc 2001;49:1700-7.
18. Boyle PA, Malloy PF, Salloway S, Cahn-Weiner DA, Cohen R, Cummings JL. Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2003;11:214-21.
19. Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998;10:314-9.
20. Mizrahi R, Starkstein SE. Epidemiology and management of apathy in patients with Alzheimer's disease. Drugs Aging 2007;24:547-54.
21. Starkstein SE, Jorge R, Mizrahi R, Robinson RG. A prospective longitudinal study of apathy in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006;77:8-11. (Pubitemid 43022682)
22. Boyle PA, Malloy PF. Treating apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 2004;17:91-9.
23. Padala PR, Burke WJ, Shostrom VK, et al. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry;18:371-4.
24. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-5.
25. Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriatr Psychiatry 2005;13:460-8.
26. Devanand DP, Brockington CD, Moody BJ, et al. Behavioral syndromes in Alzheimer's disease. Int Psychogeriatr 1992;4 (suppl 2):161-84.
27. Freels S, Cohen D, Eisdorfer C, et al. Functional status and clinical findings in patients with Alzheimer's disease. J Gerontol 1992;47:M177-82.
28. Greene JG, Smith R, Gardiner M, Timbury GC. Measuring behavioural disturbance of elderly demented patients in the community and its effects on relatives: a factor analytic study. Age Ageing 1982;11:121-6.
29. Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998;46:210-5.
30. Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998;51(1 suppl 1):S2-17; discussion S65-7.
31. Imbimbo BP, Lombard J, Pomara N. Pathophysiology of Alzheimer's disease. Neuroimaging Clin North Am 2005;15:727-53.
32. Mohs RC, Shiovitz TM, Tariot PN, Porsteinsson AP, Baker KD, Feldman PD. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. Am J Geriatr Psychiatry 2009;17:752-9.
33. Peskind ER, Tsuang DW, Bonner LT, et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord 2005;19:23-8.
34. Herrmann N, Lanctot KL, Eryavec G, Khan LR. Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients. J Psychopharmacol 2004;18:215-20.
35. Lindenmayer JP. The pathophysiology of agitation. J Clin Psychiatry 2000;61(suppl 14):5-10.
36. Matthews KL, Chen CP, Esiri MM, Keene J, Minger SL, Francis PT. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry 2002;51:407-16.
37. Pizzolato G, Chierichetti F, Fabbri M, et al. Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer [123I]-IBZM. Neurology 1996;47:1065-8.
38. Tanaka Y, Meguro K, Yamaguchi S, et al. Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease. Ann Nucl Med 2003;17:567-73.
39. Hodges JR, Davies RR, Xuereb JH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004;56:399-406.
40. Huey ED, Garcia C, Wassermann EM, Tierney MAM, Grafman J. Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry 2008;69:1981-2.
41. Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006;66:17-22.
42. David R, Koulibaly M, Benoit M, et al. Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases. A SPECT study with partial volume effect correction. Clin Neurol Neurosurg 2008;110:19-24.
43. Engelborghs S, Vloeberghs E, Le Bastard N, et al. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int 2008;52:1052-60.
44. Reeves S, Brown R, Howard R, Grasby P. Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology 2009;72:528-34.
45. Roselli F, Pisciotta NM, Perneczky R, et al. Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Mov Disord 2009;24:2097-103.
46. Bressan RA, Crippa JA. The role of dopamine in reward and pleasure behaviour-review of data from preclinical research. Acta Psychiatr Scand Suppl 2005(427):14-21.
47. Herrmann N, Rothenburg LS, Black SE, et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol 2008;28:296-301.
48. Lanctot KL, Moosa S, Herrmann N, et al. A SPECT study of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;24:65-72.
49. Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology 2006;31:651-8.
50. Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998;155:1325-31.
51. Baranski JV, Pigeau R, Dinich P, Jacobs I. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol 2004;19:323-32.
52. Padala PR, Burke WJ, Bhatia SC. Modafinil therapy for apathy in an elderly patient. Ann Pharmacother 2007;41:346-9. DOI 10.1345/aph.1H302
53. Wilens TE. Mechanism of action of agents used in attention-deficit/ hyperactivity disorder. J Clin Psychiatry 2006;67(suppl 8):32-8.
54. Kaufmann MW, Cassem NH, Murray GB, Jenike M. Use of psychostimulants in medically ill patients with neurological disease and major depression. Can J Psychiatry 1984;29:46-9.
55. Padala PR, Burke WJ, Bhatia SC, Petty F. Treatment of apathy with methylphenidate. J Neuropsychiatry Clin Neurosci 2007;19:81-3.
56. Galynker I, Ieronimo C, Miner C, Rosenblum J, Vilkas N, Rosenthal R. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci 1997;9:231-9.
57. Kaplitz SE. Withdrawn, apathetic geriatric patients responsive to methylphenidate. J Am Geriatr Soc 1975;23:271-6.
58. Marin RS, Butters MA, Mulsant BH, Pollock BG, Reynolds CF 3rd. Apathy and executive function in depressed elderly. J Geriatr Psychiatry Neurol 2003;16:112-6.
59. Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. J Nerv Ment Dis 1994;182:235-9.
60. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991;38:143-62.
61. Branconnier RJ, Cole JO. The therapeutic role of methylphenidate in senile organic brain syndrome. Proc Annu Meet Am Psychopathol Assoc 1980;69:183-96.
62. Roccaforte WH, Burke WJ. Use of psychostimulants for the elderly. Hosp Community Psychiatry 1990;41:1330-3.
63. Anderson KN, Hatfield C, Kipps C, Hastings M, Hodges JR. Disrupted sleep and circadian patterns in frontotemporal dementia. Eur J Neurol 2009;16:317-23.
64. Boddy F, Rowan EN, Lett D, O'Brien JT, McKeith IG, Burn DJ. Subjectively reported sleep quality and excessive daytime somnolence in Parkinson's disease with and without dementia, dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:529-35.
65. Deschenes CL, McCurry SM. Current treatments for sleep disturbances in individuals with dementia. Curr Psychiatry Rep 2009;11:20-6.
66. Lee JH, Bliwise DL, Ansari FP, et al. Daytime sleepiness and functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2007;15:620-6.
67. Martin JL, Ancoli-Israel S. Sleep disturbances in long-term care. Clin Geriatr Med 2008;24:39-50.
68. Rao V, Spiro J, Samus QM, et al. Insomnia and daytime sleepiness in people with dementia residing in assisted living: findings from the Maryland Assisted Living Study. Int J Geriatr Psychiatry 2008;23:199-206.
69. NIH state-of-the-science conference statement on manifestations and management of chronic insomnia in adults. NIH Consens Sci Statements 2005;22:1-30.
70. Cooke JR, Loredo JS, Liu L, et al. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease. Drugs Aging 2006;23:503-11.
71. Kittur S, Hauser P. Improvement of sleep and behavior by methylphenidate in Alzheimer's disease. Am J Psychiatry 1999;156:1116-7.
72. Howcroft DJ, Jones RW. Does modafinil have the potential to improve disrupted sleep patterns in patients with dementia? Int J Geriatr Psychiatry 2005;20:492-5.
73. Crook T, Ferris S, Sathananthan G. The effect of methylphenidate on test performance in the cognitively impaired aged. Psychopharmacol Bull 1977;13:46-8.
74. Product information. Ritalin (methylphenidate). East Hanover, NJ: Novartis Pharmaceuticals, April 2009.
75. Product information. Dexedrine (dextroamphetamine). Research Triangle Park, NC: GlaxoSmithKline, September 2009.
76. Product information. Strattera (atomoxetine). Indianapolis, IN: Eli Lilly and Company, June 2009.
77. Product information. Provigil (modafinil). Frazer, PA: Cephalon, March 2008.
78. United States Food and Drug Administration. FDA directs ADHD drug manufacturers to notify patients about cardiovascular and psychiatric adverse events. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ ucm108849.htm (accessed 2010 Apr 26).
79. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003;163:2716-24.
80. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2009;121:948-54.
81. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66.
82. Product information. Nuvigil (armodafinil). Frazer, PA: Cephalon, January 2010.
83. Verkaik R, van Weert JC, Francke AL. The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review. Int J Geriatr Psychiatry 2005;20:301-14.
84. United States National Institutes of Health. ClinicalTrials.gov. http://www.clinicaltrials.gov (accessed 2010 June 30).